Zicheng Yu, Peijun Zhou, Da Xu, Xianghui Wang, Hongzhuan Chen
Ruijin Hospital and Medical School of Shanghai Jiao Tong University, Shanghai, PR China.
Br J Clin Pharmacol. 2006 Oct;62(4):446-52. doi: 10.1111/j.1365-2125.2006.02626.x.
To characterize the pharmacokinetics of mycophenolic acid (MPA) in Chinese renal transplant patients.
Thirty-one renal transplant patients (17 male, 14 female) receiving mycophenolate mofetil (MMF) 1.0 g twice daily were included in this study. A pharmacokinetic study was performed during an interval in dosing after steady state had been reached within 2 months after transplantation. The plasma MPA concentration were measured by high-performance liquid chromatography (HPLC) at 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 12 h after the administration of a single dose. Pharmacokinetic parameters were calculated with 3P97 software. SAS software was used for statistical analysis. Multiple linear regression analysis was used to determine limited sampling approaches.
The mean peak plasma concentration (C(max)) and area under the concentration-time curve (AUC(0-12)) were 19.67 +/- 8.21 microg ml(-1) and 52.16 +/- 12.50 microg h ml(-1), but there was large variability in these pharmacokinetic parameters. Regression analysis between each plasma concentration and AUC for the limited sampling strategy of MMF therapeutic drug monitoring demonstrated that each of the concentrations at 0.5, 1, 4 and 10 h was positively correlated with AUC (r = 0.60, P = 0.0004; r = 0.60, P = 0.0003; r = 0.61, P = 0.0003; r = 0.64, P = 0.0001, respectively). The combined use of these four samples explained over 90% of the variance in the total (nine-point) AUC(0-12). A formula was obtained for the assessment of MPA AUC based on four samples: MPA AUC = 12.61 + 0.37 x C(0.5) + 0.49 x C(1) + 3.22 x C(4) + 8.17 x C(10).
Chinese renal transplant patients had higher median AUCs than caucasians and African-Americans. As in other studies, there was large interindividual variability. A limited four-point AUC was in good agreement with the 12-h AUC and provided the basis of a predictive formula.
研究霉酚酸(MPA)在中国肾移植患者中的药代动力学特征。
本研究纳入31例肾移植患者(男17例,女14例),这些患者接受霉酚酸酯(MMF)每日2次,每次1.0 g的治疗。在移植后2个月内达到稳态后的给药间隔期进行药代动力学研究。单次给药后0.5、1、1.5、2、4、6、8、10和12小时,采用高效液相色谱法(HPLC)测定血浆MPA浓度。使用3P97软件计算药代动力学参数。采用SAS软件进行统计分析。运用多元线性回归分析确定有限采样方法。
血浆平均峰浓度(C(max))和浓度-时间曲线下面积(AUC(0 - 12))分别为19.67±8.21μg ml(-1)和52.16±12.50μg h ml(-1),但这些药代动力学参数存在较大变异性。MMF治疗药物监测有限采样策略下各血浆浓度与AUC之间的回归分析表明,0.5、1、4和10小时的各浓度与AUC均呈正相关(r分别为0.60,P = 0.0004;r = 0.60,P = 0.0003;r = 0.61,P = 0.0003;r = 0.64,P = 0.0001)。这四个样本的联合使用解释了总(九点)AUC(0 - 12)中超过90%的变异。基于四个样本获得了评估MPA AUC的公式:MPA AUC = 12.61 + 0.37×C(0.5) + 0.49×C(1) + 3.22×C(4) + 8.17×C(10)。
中国肾移植患者的AUC中位数高于白种人和非裔美国人。与其他研究一样,个体间存在较大变异性。有限的四点AUC与12小时AUC高度一致,并提供了预测公式的基础。